{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-017151","form_type":"8-K","ticker":"ELTP","cik":"0001053369","company_name":"ELITE PHARMACEUTICALS INC /NV/","filed_at":"2025-06-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.336177+00:00","generated_at":"2026-05-18T11:52:46.349512+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Elite Pharma FY2025 revenue $84.0M (+48% YoY); operating profit $19.6M (+81% YoY)","bullets":["Consolidated revenue for FY2025 (ended March 31, 2025) was $84.0M, up 48% from $56.6M prior year.","Operating profit rose 81% to $19.6M, driven by lisdexamfetamine products launched in FY2025 and Elite label product lines.","Conference call scheduled for July 1, 2025 at 11:30 AM EDT to discuss results and business update.","Company requests stockholder questions be submitted by 7:00 PM EDT on June 30, 2025.","No EPS or net income figures disclosed in the press release; full 10-K filed separately."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-017151","json":"https://secwatch.observer/filing/0001641172-25-017151.json","markdown":"https://secwatch.observer/filing/0001641172-25-017151.md","text":"https://secwatch.observer/filing/0001641172-25-017151.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053369/000164117225017151/0001641172-25-017151-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053369/000164117225017151/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T11:52:46.349512+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}